Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular and cellular paradigms of multidrug resistance in cancer
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, et al.
Cancer Reports (2020) Vol. 5, Iss. 12
Open Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Alisha Ramos, Samira Sadeghi, Hossein Tabatabaeian
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9451-9451
Open Access | Times Cited: 169
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Yanghong Ni, Xiaoting Zhou, Jia Yang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 104
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Chenmala Karthika, R. Sureshkumar, Mehrukh Zehravi, et al.
Life (2022) Vol. 12, Iss. 6, pp. 897-897
Open Access | Times Cited: 79
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
Ebrahim H. Maleki, Ahmad Reza Bahrami, Maryam Moghaddam Matin
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 189-204
Open Access | Times Cited: 57
Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review
Shijia Zhao, Jie Liu, Zaosheng Lv, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115254-115254
Closed Access | Times Cited: 49
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Nauf Bou Antoun, Athina‐Myrto Chioni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12222-12222
Open Access | Times Cited: 43
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 32
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
Kenneth K.W. To, Zoufang Huang, Hang Zhang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101058-101058
Closed Access | Times Cited: 20
lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili, Eyhab Ali, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 18
Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components
Entaz Bahar, Sun‐Young Han, Ji‐Ye Kim, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1462-1462
Open Access | Times Cited: 45
Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer
Pradhapsingh Bharathiraja, Priya Yadav, Andaleeb Sajid, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101004-101004
Open Access | Times Cited: 38
Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy
Yedi Herdiana, Nasrul Wathoni, Dolih Gozali, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 879-879
Open Access | Times Cited: 30
Soluplus® as a solubilizing excipient for poorly water-soluble drugs: Recent advances in formulation strategies and pharmaceutical product features
Mohamed S. Attia, Ahmed Elshahat, Ahmed Hamdy, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104519-104519
Closed Access | Times Cited: 24
Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 680-680
Open Access | Times Cited: 15
Unveiling Green Synthesis and Biomedical Theranostic paradigms of Selenium Nanoparticles (SeNPs) - A state-of-the-art comprehensive update
Sagnik Nag, Shinjini Kar, Shatakshi Mishra, et al.
International Journal of Pharmaceutics (2024) Vol. 662, pp. 124535-124535
Open Access | Times Cited: 13
CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer
Chunge Zhong, Wenjie Jiang, Yingjia Yao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde
Yusuff Olayiwola, Lauren Gollahon
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 361-361
Open Access | Times Cited: 9
A second life for MAO inhibitors? From CNS diseases to anticancer therapy
Sabina Sblano, Angelina Boccarelli, Francesco Mesiti, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116180-116180
Open Access | Times Cited: 8
Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics
Manish Kumar
(2025)
Closed Access | Times Cited: 1
Autophagy orchestrates resistance in hepatocellular carcinoma cells
Homeyra Seydi, Kosar Nouri, Niloufar Rezaei, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114487-114487
Open Access | Times Cited: 21
Rumex vesicarius L. boosts the effectiveness of sorafenib in triple-negative breast cancer by downregulating BCl2, mTOR, and JNK, and upregulating p21 expression
Aml Ghanem, Mohamed A. Ali, Mohamed A. Elkady, et al.
Pathology - Research and Practice (2023) Vol. 250, pp. 154807-154807
Closed Access | Times Cited: 19
Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells
Qi Wang, Chung-Hui Huang, Fajar Setyo Wibowo, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 11, pp. 13509-13524
Closed Access | Times Cited: 7
Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments
Konstantinos Avgoustakis, Athina Angelopoulou
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 179-179
Open Access | Times Cited: 6
Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies
Lenka Trnkova, Verona Buociková, Michal Mego, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116559-116559
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top